Phase 3 Psilocybin Trial Success and $150M Offering Boost Cybin’s Prospects
Compass Pathways reported a 3.8-point MADRS improvement at p<0.001 in its Phase 3 COMP006 trial, sending its shares up 33% before unveiling a $150 million offering at $4.275 per share (44% discount). The clinical validation has de-risked psilocybin therapies and lifted Cybin’s development outlook for CYB003.
1. Compass Pathways Phase 3 Breakthrough
Compass Pathways reported that its Phase 3 COMP006 trial of the COMP360 psilocybin formulation achieved a 3.8-point mean MADRS score reduction versus active control (p<0.001), a 39% response rate at Week 6, rapid symptom relief from Day 1 and no major safety imbalances in suicidal ideation.
2. Dilutive Offering and Market Reaction
Following the data release that drove a 33% stock surge and 34 million share volume, the company launched a $150 million public offering at $4.275 per share, a 44% discount to the prior close, triggering pre-market selling before shares resumed upward momentum.
3. Positive Ripple for Cybin’s CYB003 Program
This clinical validation of synthetic psilocybin has de-risked the mechanism of action for the sector and strengthened the outlook for Cybin’s deuterated psilocybin analog CYB003 by potentially streamlining FDA trial design and attracting investor capital.